Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting

MORRISTOWN, N.J., May 07, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, announced today that it will present data on its portfolio, including results from its real-world registry studies of VABOMERE^® (meropenem and vaborbactam), ORBACTIV^® (oritavancin), and MINOCIN^® (minocycline) for Injection at the upcoming Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting held from May 8-11 2019 in Orlando, Florida.